**5. Conclusions**

Based on our model, local administration of the rhGH accelerates the wound healing process and improves the quality of human skin. The healing rate was twice as fast in the rhGH group compared to the control group. In the rhGH treatment group, we found an increase in dermis regeneration tissue with a delay in the maturation period, which potentially improves the re-epithelialization process. Based on the macroscopical and histological findings and considering the human skin component of this model, the rhGH may have a clinical use in pressure ulcer treatment, and further studies remain to be performed. We think that our findings could be extrapolated to other compromised wound healing situations such as diabetic or chronic ischemia patients.

**Author Contributions:** conceptualization, A.A.M. and J.B.; methodology, L.C., A.A.M., N.G.-H. and M.Á.-M.; validation, L.C., N.d.l.R., M.A.O.; formal analysis, L.C., M.A.O., A.A.M.; investigation, L.C., N.d.l.R., M.A.O., A.A.M.; writing—original draft preparation, L.C.; writing—review and editing, L.C., A.A.M. and J.B.; funding acquisition, J.B., N.G.-H., A.A.M. and M.Á.-M.

**Funding:** This study was supported by Community of Madrid (B2017/BMD-3804 MITIC-CM) and Fundación MAPFRE (SA/11/AYU/444). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Acknowledgments:** We thank the Department of Plastic Surgery and Burns and the Department of Pharmacy, University Hospital of Getafe, Madrid, Spain; and Mario Arenillas (Biomedical Research Foundation of the University Hospital of Getafe, Madrid, Spain).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
